Abbott India Ltd vs Astrazeneca Pharma India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Abbott India Ltd is ₹ 25323 as of 05 May 15:30 . The P/E Ratio of Abbott India Ltd changed from 46.1 on March 2021 to 46.2 on March 2025 . This represents a CAGR of 0.04% over 5 yearsThe P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 years The Market Cap of Abbott India Ltd changed from ₹ 31850 crore on March 2021 to ₹ 65302 crore on March 2025 . This represents a CAGR of 15.44% over 5 yearsThe Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 years The revenue of Abbott India Ltd for the Dec '25 is ₹ 1793 crore as compare to the Sep '25 revenue of ₹ 1827 crore. This represent the decline of -1.82% The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The ebitda of Abbott India Ltd for the Dec '25 is ₹ 533.23 crore as compare to the Sep '25 ebitda of ₹ 572.12 crore. This represent the decline of -6.8% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The net profit of Abbott India Ltd changed from ₹ 328.01 crore to ₹ 375.96 crore over 7 quarters. This represents a CAGR of 8.11% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Abbott India Ltd changed from 84.61 % on March 2021 to 71.36 % on March 2025 . This represents a CAGR of -3.35% over 5 yearsThe Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 years .

About Abbott India Ltd

Abbott India Limited was originally incorporated on August 22, 1944 as Boots Pure Drug Company (India) Limited.
The company name was changed to 'The Boots Company (India) Limited' on November 1, 1971, thereafter to Boots Pharmaceuticals Limited on January 1, 1991.
In October, 1995 the name was changed to Knoll Pharmaceuticals Limited, and in July, 2002, they got their present name 'Abbott India Limited'. Company is one of the leading multinational pharmaceutical companies in India and operates with an owned manufacturing facility in Goa and various independent contract/third party manufacturers based across the country.
The Company sells its products through independent distributors primarily within India.
It provides products and solutions across various therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, Consumer Health, etc.

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

FAQs for the comparison of Abbott India Ltd and Astrazeneca Pharma India Ltd

Which company has a larger market capitalization, Abbott India Ltd or Astrazeneca Pharma India Ltd?

Market cap of Abbott India Ltd is 54,031 Cr while Market cap of Astrazeneca Pharma India Ltd is 20,116 Cr

What are the key factors driving the stock performance of Abbott India Ltd and Astrazeneca Pharma India Ltd?

The stock performance of Abbott India Ltd and Astrazeneca Pharma India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Abbott India Ltd and Astrazeneca Pharma India Ltd?

As of May 5, 2026, the Abbott India Ltd stock price is INR ₹25426.7. On the other hand, Astrazeneca Pharma India Ltd stock price is INR ₹8046.55.

How do dividend payouts of Abbott India Ltd and Astrazeneca Pharma India Ltd compare?

To compare the dividend payouts of Abbott India Ltd and Astrazeneca Pharma India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.